Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track

Tyra Biosciences, Inc.

Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.
Cash and cash equivalents $302.2M at year-end 2021; no revenue reported.
IND for TYRA-300 (FGFR3) expected mid-2022; TYRA-200 (FGFR2) in H2 2022.
Appointed Allison Kemner as VP Clinical Sciences and Operations in Q4 2021.
Added to Russell 2000 Index in December 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.